Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

472 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma.
Dosne AG, Li X, Luo MM, Nnane I, Dimopoulos MA, Terpos E, Sonneveld P, Kampfenkel T, Carson R, Amin H, Perez Ruixo J, Zhou H, Sun YN, Xu Y. Dosne AG, et al. Among authors: sun yn. Br J Clin Pharmacol. 2023 May;89(5):1640-1655. doi: 10.1111/bcp.15628. Epub 2022 Dec 28. Br J Clin Pharmacol. 2023. PMID: 36484341 Free article. Clinical Trial.
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
Xu XS, Dimopoulos MA, Sonneveld P, Ho PJ, Belch A, Leiba M, Capra M, Gomez D, Medvedova E, Iida S, Min CK, Schecter J, Jansson R, Zhang L, Sun YN, Clemens PL. Xu XS, et al. Among authors: sun yn. Adv Ther. 2018 Nov;35(11):1859-1872. doi: 10.1007/s12325-018-0815-9. Epub 2018 Oct 29. Adv Ther. 2018. PMID: 30374808 Free PMC article.
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
Xu XS, Moreau P, Usmani SZ, Lonial S, Jakubowiak A, Oriol A, Krishnan A, Bladé J, Luo M, Sun YN, Zhou H, Nnane I, Deraedt W, Qi M, Ukropec J, Clemens PL. Xu XS, et al. Among authors: sun yn. Adv Ther. 2020 Apr;37(4):1464-1478. doi: 10.1007/s12325-020-01247-8. Epub 2020 Feb 20. Adv Ther. 2020. PMID: 32078124 Free PMC article. Clinical Trial.
Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients.
Luo MM, Usmani SZ, Mateos MV, Nahi H, Chari A, San-Miguel J, Touzeau C, Suzuki K, Kaiser M, Carson R, Heuck C, Qi M, Zhou H, Sun YN, Parasrampuria DA. Luo MM, et al. Among authors: sun yn. J Clin Pharmacol. 2021 May;61(5):614-627. doi: 10.1002/jcph.1771. Epub 2020 Nov 3. J Clin Pharmacol. 2021. PMID: 33145788 Free PMC article.
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Girgis S, Lin SXW, Pillarisetti K, Banerjee A, Stephenson T, Ma X, Shetty S, Yang TY, Hilder BW, Jiao Q, Hanna B, Adams HC 3rd, Sun YN, Sharma A, Smit J, Infante JR, Goldberg JD, Elsayed Y. Girgis S, et al. Among authors: sun yn. Target Oncol. 2022 Jul;17(4):433-439. doi: 10.1007/s11523-022-00893-y. Epub 2022 Jun 24. Target Oncol. 2022. PMID: 35749004 Free PMC article. Clinical Trial.
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Girgis S, Lin SXW, Pillarisetti K, Banerjee A, Stephenson T, Ma X, Shetty S, Yang TY, Hilder BW, Jiao Q, Hanna B, Adams HC 3rd, Sun YN, Sharma A, Smit J, Infante JR, Goldberg JD, Elsayed Y. Girgis S, et al. Among authors: sun yn. Target Oncol. 2022 Sep;17(5):609. doi: 10.1007/s11523-022-00904-y. Target Oncol. 2022. PMID: 35913648 Free PMC article. No abstract available.
472 results